Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2022 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches

Eurostars-3 collaborative project with Danish institutions ImProTher and University of Copenhagen Global budget of 1.4 million euros; Oryzon to receive up to 400,000 euros Project will assess the...
December 12, 2022 12:24 ET | Source: Oryzon Genomics, S.A.

ORYZON Presents Final Data From Phase IIa ALICE Trial in Unfit AML Patients with First-line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022

Robust, rapid and durable efficacy - ORR 81%, of which 64% are CR/CRi68% of CR/CRi lasting more than 6 monthsLongest remission + 3 yearsIadademstat and azacitidine combination shows a good safety...
November 09, 2022 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Collaborative study with Fox Chase Cancer Center (FCCC)Oryzon and FCCC will collaborate to assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECs MADRID and SPAIN and...
November 07, 2022 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society of Hematology Annual Conference

MADRID, Spain and BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
November 04, 2022 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Give Updates on Corporate Progress in November

Kabuki Syndrome Foundation Annual Conference11th Drug Discovery Strategic SummitInv€$tival Showcase LSX Leaders 2022Jefferies London Healthcare Conference 2022 MADRID, Spain and BOSTON, Nov. 04,...
November 02, 2022 07:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2022

MADRID, Spain and BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...
October 03, 2022 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Give Updates on Corporate Progress in October

Chardan's 6th Annual Genetic Medicines Conference MSD European Business Development Outreach Iberian Digital Forum AACR Special Conference: Cancer Epigenomics Brain Innovation Days HealthTech...
September 16, 2022 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

At the 10th European Conference on Mental Health (ECMH)Company expects to perform an interim analysis in 1Q23 MADRID, Spain and BOSTON, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
September 08, 2022 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Give Updates on Corporate Progress in September

H.C. Wainwright Global Investment Conference10th European Conference on Mental HealthSachs Annual Biotech in Europe ForumAnnual RAS-Targeted Drug Development SummitXIX Congress of the Spanish Society...
July 26, 2022 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Collaborates with the CMT Research Foundation in the US

To explore Oryzon’s HDAC6 inhibitors on Charcot-Marie-Tooth diseaseCMTRF to provide funding for in vivo efficacy tests in CMT preclinical model MADRID and BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- ...